Skip to main content
. 2020 Nov 3;95(18):e2487–e2499. doi: 10.1212/WNL.0000000000010600

Figure 3. Reduction in monthly migraine days.

Figure 3

Mean change from baseline in monthly number of migraine days for patients in fremanezumab monthly and quarterly groups during the long-term study is shown for (A) patients with chronic migraine (CM) and (B) patients with episodic migraine (EM). Percentage of patients with at least 50% reduction from baseline in monthly average number of migraine days for patients in fremanezumab quarterly and monthly groups during the long-term study is shown for (C) patients with CM and (D) patients with EM. BL = baseline; SE = standard error.